| (Values in U.S. Thousands) | Jun, 2023 | Mar, 2023 | Dec, 2022 | Sep, 2022 | Jun, 2022 |
| Sales | 1,010 | 1,830 | 510 | 2,500 | 420 |
| Sales Growth | -44.81% | +258.82% | -79.60% | +495.24% | -84.44% |
| Net Income | -66,940 | -60,180 | -62,550 | -55,980 | -37,650 |
| Net Income Growth | -11.23% | +3.79% | -11.74% | -48.69% | -18.84% |
Chinook Therapeutics Inc (KDNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Chinook Therapeutics, Inc. is a clinical-stage biotechnology company. It focuses on developing precision medicines for kidney diseases. Chinook Therapeutics, Inc., formerly known as Aduro Biotech Inc., is based in BERKELEY, Calif.
Fiscal Year End Date: 12/31